You have no items in your shopping cart.
Product Details
| Alternate Name | T-cell growth factor (TCGF), Aldesleukin, Lymphokine, IL-2. |
|---|---|
| Gene Symbol | IL2 |
| Gene ID | 3558 |
| Accession # | P60568 |
| Source | E. coli |
| Appearance | Lyophilized protein |
| Physical Form Description | Lyophilized with no additives. |
| Molecular Weight | 15.5 kDa |
| Purity by SDS-PAGE | > 95% |
| Biological Activity | The ED50 as determined by the dose-dependent stimulation of murine CTLL-2 cells is ≤ 10 ng/ml, corresponding to a specific activity of ≥ 1 x 10⁵ units/mg. |
| Reconstitution Instructions | Reconstitute in H₂O to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers or stored at 4°C for 1 week or –20°C for future use. |
| Handling | Centrifuge the vial prior to opening. |
| Storage Conditions | -20°C |
| Shipping Conditions | Gel Pack |
| USAGE | For Research Use Only! Not to be used in humans |
Details
IL-2 is a potent immuno-modulator, which mediates a wide range of immune and inflammatory responses. Recombinant Human IL-2 is a 15.5 kDa protein containing 134 amino acid residues.
Why buy BioVision Products?
 |
 |
 |
 |
Innovation |
Affordability |
Global Presence |
Technical Support |
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways. |
BioVision is committed to providing the highest quality products at a competitive price. |
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery. |
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently. |
Du et al., CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells. Cancer Immunology, Sep 2014; 2: 878 - 889.
Schneiders et al., CD1d-Restricted Antigen Presentation by V
9V
2-T Cells Requires Trogocytosis. Cancer Immunology, Aug 2014; 2: 732 - 740.
9V2-T Cells Requires Trogocytosis. Cancer Immunology, Aug 2014; 2: 732 - 740.For more citations of this product click here
